Benzylthiouracil (BTU) is an antithyroid preparation. It is a thioamide, closely related to propylthiouracil.
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.026.106 |
Chemical and physical data | |
Formula | C11H10N2OS |
Molar mass | 218.27 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Adverse effects
editBenzylthiouracil has been associated with severe adverse effects, notably vasculitis and subsequent ANCA-positive glomerulonephritis, as well as isolated reports of lung damage.[1][2][3][4]
References
edit- ^ Tieulie N, Huong DL, Andreu M, et al. (2002). "[ANCA associated glomerulonephritis related to benzylthiouracil]". Rev Méd Interne (in French). 23 (10): 853–6. doi:10.1016/S0248-8663(02)00694-X. PMID 12428489.
- ^ Kaaroud H, Khiari K, Ben Moussa F, Barbouch S, Boussema E, Ben Maïz H (2002). "[Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves disease]". Rev Méd Interne (in French). 23 (10): 857–61. doi:10.1016/S0248-8663(02)00704-X. PMID 12428490.
- ^ Braham A, Houman MH, Rais L, Ben Gborbel I, Lamloum M, Miled M (2004). "[Benzylthiouracil induced ANCA-positive vasculitis]". Presse Médicale (in French). 33 (19 Pt 1): 1331–3. doi:10.1016/S0755-4982(04)98919-1. PMID 15615240.
- ^ Thabet F, Sghiri R, Tabarki B, Ghedira I, Yacoub M, Essoussi AS (2006). "ANCA-associated diffuse alveolar hemorrhage due to benzylthiouracil". Eur J Pediatr. 165 (7): 435–6. doi:10.1007/s00431-005-0053-4. PMID 16622664.